Jen Smith

Patients with mHSPC who receive enzalutamide plus ADT are 4 times more likely to achieve undetectable PSA levels than patients who receive ADT alone, according to an analysis of data from the ARCHES trial.

Real-world data support first-line palbociclib plus an aromatase inhibitor as standard care for HR+, HER2- metastatic breast cancer, according to researchers.

The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.

Researchers found that socioeconomic status, insurance, race, and rurality were all associated with telemedicine use.

Most patients completed at-home chemotherapy infusions as planned, and no one stopped treatment because of adverse drug reactions.